Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy

Marcella Nebbioso, Ludovico Alisi, Francesca Giovannetti, Marta Armentano, Alessandro LambiaseDepartment of Sense Organs, Faculty of Medicine and Odontology, Umberto I Policlinic, Sapienza University of Rome, Rome 00185, ItalyAbstract: Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nebbioso M, Alisi L, Giovannetti F, Armentano M, Lambiase A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	atopy conjunctivitis cyclosporin keratitis ocular inflammation vernal keratoconjunctivitis. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/be422bc5fe2d4037a3cf2dd46da4b151
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be422bc5fe2d4037a3cf2dd46da4b151
record_format	dspace
spelling	oai:doaj.org-article:be422bc5fe2d4037a3cf2dd46da4b1512021-12-02T07:07:45ZEye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy1177-5483https://doaj.org/article/be422bc5fe2d4037a3cf2dd46da4b1512019-07-01T00:00:00Zhttps://www.dovepress.com/eye-drop-emulsion-containing-01-cyclosporin-1-mgml-for-the-treatment-o-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Marcella Nebbioso, Ludovico Alisi, Francesca Giovannetti, Marta Armentano, Alessandro LambiaseDepartment of Sense Organs, Faculty of Medicine and Odontology, Umberto I Policlinic, Sapienza University of Rome, Rome 00185, ItalyAbstract: Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease.Keywords: atopy, conjunctivitis, cyclosporin, keratitis, ocular inflammation, vernal keratoconjunctivitisNebbioso MAlisi LGiovannetti FArmentano MLambiase ADove Medical Pressarticleatopyconjunctivitiscyclosporinkeratitisocular inflammationvernal keratoconjunctivitis.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1147-1155 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopy conjunctivitis cyclosporin keratitis ocular inflammation vernal keratoconjunctivitis. Ophthalmology RE1-994
spellingShingle	atopy conjunctivitis cyclosporin keratitis ocular inflammation vernal keratoconjunctivitis. Ophthalmology RE1-994 Nebbioso M Alisi L Giovannetti F Armentano M Lambiase A Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
description	Marcella Nebbioso, Ludovico Alisi, Francesca Giovannetti, Marta Armentano, Alessandro LambiaseDepartment of Sense Organs, Faculty of Medicine and Odontology, Umberto I Policlinic, Sapienza University of Rome, Rome 00185, ItalyAbstract: Vernal keratoconjunctivitis (VKC) is a rare, recurrent and multifactorial ocular disease, which typically flares up during spring and affects especially male children and adolescents. This condition does not usually respond to common treatments with antihistamines or mast cells stabilizers, whereas corticosteroids have effective results. Corticosteroids need to be carefully administered, to avoid adverse effects, mainly the secondary development of glaucoma, cataracts, or infections. Immunosuppressive agents, such as cyclosporin (CyA) or tacrolimus are, therefore, frequently employed in VKC patients. Only the 0.1% CyA (1 mg/mL) concentration has an approved and specific clinical indication for the treatment of VKC and this drug was given the denomination of orphan drug by the European Commission (EU/3/06/360) in 2006. So far, few studies have been conducted to evaluate the efficacy and the side effects of topical 0.1% CyA. Different topical CyA concentrations, ranging from 0.05% to 2%, and various types of formulation are available at the moment. In the future, 0.1% CyA will presumably take an important part in the management of VKC. The present review focuses on eye drops containing 0.1% CyA; however, more studies will be needed to define its long-term efficacy in the natural course of this severe ocular disease.Keywords: atopy, conjunctivitis, cyclosporin, keratitis, ocular inflammation, vernal keratoconjunctivitis
format	article
author	Nebbioso M Alisi L Giovannetti F Armentano M Lambiase A
author_facet	Nebbioso M Alisi L Giovannetti F Armentano M Lambiase A
author_sort	Nebbioso M
title	Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
title_short	Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
title_full	Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
title_fullStr	Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
title_full_unstemmed	Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
title_sort	eye drop emulsion containing 0.1% cyclosporin (1 mg/ml) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/be422bc5fe2d4037a3cf2dd46da4b151
work_keys_str_mv	AT nebbiosom eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT alisil eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT giovannettif eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT armentanom eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy AT lambiasea eyedropemulsioncontaining01cyclosporin1mgmlforthetreatmentofseverevernalkeratoconjunctivitisanevidencebasedreviewandplaceintherapy
_version_	1718399598837366784

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy

Ejemplares similares